Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
169,096,637
-
Total 13F shares
-
51,193,741
-
Share change
-
+531,253
-
Total reported value
-
$60,427,306
-
Put/Call ratio
-
7.4%
-
Price per share
-
$1.18
-
Number of holders
-
69
-
Value change
-
+$480,690
-
Number of buys
-
26
-
Number of sells
-
35
Institutional Holders of CytomX Therapeutics, Inc. - COMMON STOCK (CTMX) as of Q3 2024
As of 30 Sep 2024,
CytomX Therapeutics, Inc. - COMMON STOCK (CTMX) was held by
69 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,193,741 shares.
The largest 10 holders included
TANG CAPITAL MANAGEMENT LLC, BVF INC/IL, VANGUARD GROUP INC, JANUS HENDERSON GROUP PLC, ACADIAN ASSET MANAGEMENT LLC, Prosight Management, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., MILLENNIUM MANAGEMENT LLC, Assenagon Asset Management S.A., and JACOBS LEVY EQUITY MANAGEMENT, INC.
This page lists
69
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.